Trial Profile

A Single and Repeat Dosing Study of the Safety, Drug Exposure, and Clinical Activity of R-3750 in Patients with Mild to Moderate Ulcerative Colitis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs R 3750 (Primary)
Indications Ulcerative colitis
Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

07 Apr 2025 According to the Rise Therapeutics media release, first clinical results from the completed dose escalation segment will be presented at the Digestive Disease Week (DDW) Conference in San Diego May 3-6.
06 Jan 2025 According to the Rise Therapeutics media release, the company has completed dose escalation enrollment stages and will now initiate the planned dose expansion stages, enrolling additional patients at fixed doses in this study.
13 Nov 2024 Planned End Date changed from 1 Feb 2025 to 1 Oct 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com